Sector News

Boston Scientific to expand in Europe with Symetis buy

March 31, 2017
Life sciences

Boston Scientific Corp on Thursday agreed to buy Swiss medical device maker Symetis SA for $435 million, looking to bolster its presence in Europe after recalling a range of heart valves in the region.

Symetis is the fourth-largest player in transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, to replace a narrowed aortic valve that fails to open properly.

The company’s Acurate systems will broaden Boston Scientific’s TAVR range to include additional designs and delivery methods that cover more physicians and patients, Needham & Co analyst Mike Matson said in a client note.

Boston Scientific recalled its Lotus heart valve devices from Europe and other regions in February following reports of a faulty locking mechanism.

“This is an offensive rather than a defensive move and not simply a “stop-gap” to address the Lotus recall, shortcomings with Lotus, or IP issues,” Matson added.

Boston Scientific said it expects the Lotus valve devices to return to these markets in the fourth quarter.

The deal would not change the timeline of its Lotus device program, Boston Scientific said on a conference call.

The transaction is a bit of a head scratcher and will likely cause some concern on the Street about the program, J.P. Morgan analyst Michael Weinstein said.

Weinstein also noted Symetis had $40 million in TAVR sales in Europe last year and has seen limited growth in the last few years.

However, Jefferies analyst Raj Denhoy noted that even though the deal value seems “pretty high”, Symetis sales will likely rise by more than 30 percent with Boston Scientific’s backing.

Symetis said it halted its second attempt to go public, due to the deal, which is expected to close in the second quarter.

The company expected to raise up to 61.5 million euros ($66 million) and list on the Euronext Paris by March 31.

Boston Scientific said it expects the deal to slightly boost results in 2018 on an adjusted basis, and rise thereafter.

Shares of Boston Scientific, which competes with TAVR market leaders Edwards Lifesciences Corp and Medtronic Plc, were down 1.7 percent at $24.30 in late-morning trading.

By Divya Grover

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”